EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma

2021 ◽  
Author(s):  
Bernd Kasper ◽  
Giacomo Giulio Baldi ◽  
Herbert Ho-Fung Loong ◽  
Jonathan Trent
Keyword(s):  
Medical Treatment ◽  
Retroperitoneal Sarcoma ◽  
Special Issue ◽  
Standard Medical Treatment

scholarly journals Clinical Effectiveness of Cardiocytoprotective Therapy in Patients with Acute Coronar Syndrome (ACS) – Myocardial Infarction (MI), Who Were Performed Balloon Angioplasty and Coronary Artery Stenting

2019 ◽  
Vol 25 (1) ◽  
Author(s):  
Mykola Shved ◽  
Lesia Tsuglevych ◽  
Svitlana Heryak
Keyword(s):  
Medical Treatment ◽  
Clinical Effectiveness ◽  
Coronary Intervention ◽  
Left Ventricular ◽  
Additional Treatment ◽  
Functional Improvement ◽  
Control Group ◽  
Restorative Treatment ◽  
Coronary Syndrome ◽  
Standard Medical Treatment

The aim of the study was to increase the efficiency of restorative treatment of patients with Acute Coronary Syndrome (Miocardial Infarction) by incorporating the protocol therapy for the course of parenteral use of L-arginine and L-carnitine (Tivorel). It has been determined that patients with ACS (MI) after percutaneous coronary intervention often develop reperfusion syndrome with manifestations of left ventricular insufficiency and rhythm disturbances. Substantial clinical and functional improvement was noted under the influence of standard medical treatment in patients of control group. At the same time postinfarction remodeling with systolic and diastolic function of the heart, with the development of heart failure syndrome and endothelial dysfunction of blood vessels, and also remained resistant to extrasystole therapy, progressed. Patients in the experimental group under the influence of complex medical treatment with the inclusion of L-arginine and L-carnitine marked a significant decrease in the frequency of violations of rhythm and conduction for the second day of observation, as well as a decrease in the manifestations of post-infarction remodeling of LV, which ultimately manifested a significant improvement in myocardial contractility (EF increased by 13%) and decreased diastolic dysfunction. Improvement of the inotropic function of the heart and a significant reduction in the frequency and severity of reperfusion arrhythmias was achieved precisely due to cardiometabolic effects of L-carnitine. In addition, in patients undergoing additional treatment with L-arginine and L-carnitine after 10 days of treatment, the activity of ET-1 was significantly lowered and the concentration of nitrogen oxide metabolites in the blood plasma increased and reach the level of healthy subjects (p>0.05). So, they recovered the endothelial function of the vessels.

scholarly journals Paradoxical Herniation following Decompressive Craniectomy in the Subacute Setting

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Alex P. Michael ◽  
Jose Espinosa
Keyword(s):  
Medical Treatment ◽  
Intracranial Hypertension ◽  
Treatment Option ◽  
Decompressive Craniectomy ◽  
Supine Position ◽  
Unique Case ◽  
Adequate Hydration ◽  
Standard Medical Treatment ◽  
Uncommon Complication

Decompressive craniectomy is reserved for extreme cases of intracranial hypertension. An uncommon complication known as paradoxical herniation has been documented within weeks to months following surgery. Here we present a unique case within days of surgery. Since standard medical treatment for intracranial hypertension will exacerbate paradoxical herniation, any abrupt neurological changes following decompressive craniectomy should be carefully investigated. Immediate treatment for paradoxical herniation is placement of the patient in the supine position with adequate hydration. Cranioplasty is the ultimate treatment option.

Management of severe amiodarone-induced thyrotoxicosis after failure of standard medical treatment

2013 ◽  
Vol 60 (10) ◽  
pp. e43-e45
Author(s):  
Isabel Mateo Gavira ◽  
Francisco Vilchez López ◽  
Laura Larrán Escandón ◽  
Pilar Roldán Caballero ◽  
Manuel Aguilar Diosdado
Keyword(s):  
Medical Treatment ◽  
Standard Medical Treatment

scholarly journals The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial Study

2020 ◽  
Author(s):  
Farhad Salehzadeh ◽  
Farhad Pourfarzi ◽  
Sobhan Ataei
Keyword(s):  
Clinical Trial ◽  
Medical Treatment ◽  
Open Label ◽  
Post Discharge ◽  
Double Blind ◽  
End Points ◽  
Mortality And Morbidity ◽  
Significant Difference ◽  
Standard Medical Treatment ◽  
The Impact

Abstract Background: Severe acute respiratory syndrome COVID-19 infection has evolved into a global pandemic. This study has been designed to evaluate colchicine anti-inflammatory effect on the symptoms course, duration of hospitalization, morbidity and mortality rate, of COVID-19 patients.Methods: In this prospective, open-label, randomized and double blind clinical trial, 100 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from May 21 to June 20, 2020, to either standard medical treatment (Hydroxychloroquine) or colchicine with standard medical treatment. The study took place in Imam Reza hospital of Ardabil city in Iran, with trial registration ID: 47707 (irct.ir). Colchicine group were received 1 mg tablet of colchicine daily alongside the Hydroxychloroquine for 6 days. Primary end points were (1) Length of hospitalization; (2) symptoms and (3) Co-existed disease. Secondary end points were examined 2 weeks after discharge and included (1) mortality and morbidity; (2) re-admission and (3) symptoms. Results: Overall, 100 patients (59 [59%] female; median age, 56 years) fulfilled the admission criteria and were included and randomized at 2 clinical groups. There was no significant difference between the two groups in terms of age and sex. Two groups were not significantly different in terms of underlying diseases and various clinical and para clinical findings although there were not any different during Post-discharge follow-up except for duration of fever (P<0.05). Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful. Conclusion: Colchicine can be effective in reducing systemic symptoms of COVID-19 by inhibiting inflammatory biomarkers.Current Controlled prospective Trials registration ID that has been approved by ICMJE and WHO ICTRP registry is IRCT20200418047126N1, and the date of registration is 2020-05-14.

scholarly journals Special Issue: State of the Art in Research on Acupuncture Treatment

2021 ◽  
Vol 10 (24) ◽  
pp. 5943
Author(s):  
Younbyoung Chae ◽  
Myeong Soo Lee ◽  
Yi-Hung Chen
Keyword(s):  
Medical Treatment ◽  
Acupuncture Treatment ◽  
State Of The Art ◽  
The Body ◽  
Special Issue

Acupuncture is a medical treatment that involves inserting a needle into the body [...]

Abstract WP12: Impact of the Introduction of Endovascular Treatment on Acute Ischemic Stroke Therapy in a Rural Broad Region in Japan

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Taichiro Imahori
Keyword(s):  
Ischemic Stroke ◽  
Medical Treatment ◽  
Endovascular Treatment ◽  
Acute Ischemic Stroke ◽  
Group 2 ◽  
Revascularization Therapy ◽  
Standard Medical Treatment ◽  
Iv Tpa ◽  
Broad Region ◽  
Group 1

Background: Endovascular treatment (EVT) has been proven to be effective for selected patients with acute ischemic stroke (AIS). We evaluated the effect of the introduction of EVT on outcome of AIS therapy in a rural broad region in Japan, covering an area within a radius of 80km by air ambulance. Methods: Between January 2014 and July 2016, 210 consecutive patients with acute large vessel occlusion (189 patients in the anterior circulation and 21 in the posterior circulation) admitted to our institute were analyzed. EVT was introduced into the AIS therapy at our institute in April 2015. We compared the outcome of the patients during the period before (group 1: standard medical treatment including intravenous [IV] tPA) and after (group 2: standard medical treatment including IV tPA with or without EVT) the introduction of EVT. Results: In the group 1, all 87 patients (median age, 81 years; NIHSS, 20; ASPECTS, 8; onset to door, 237min; IV tPA 24%) were treated medically (Table 1). In the group 2, among 123 patients (age, 82 years; NIHSS, 20; ASPECTS, 8; onset to door, 149min; IV tPA 16%), 47 patients were treated medically, and the remaining 76 patients underwent EVT (TICI 2b or 3, 84%). Although the median transfer distance increased (23km in the group 1 vs 30km in the group 2, p=0.028), the median time from call to admission was equivalent (42min vs 43min, p=0.93) because of the increase in the proportion of the helicopter transfer (30% vs 41%, p=0.14). The rates of patients who underwent revascularization therapy with IV tPA or EVT (24% vs 66%, p<0.001) and good outcome (mRS 0 to 2) at discharge (11% vs 24%, p=0.021) increased significantly after the introduction of EVT approach. Conclusions: Our study showed that the introduction of EVT improved the outcome of the AIS therapy with significant increase in the number of patients receiving revascularization therapy. EVT in collaboration with air ambulance might expand the target area for revascularization therapy in a rural broad region.

Sign in / Sign up

Export Citation Format

Share Document